One more pharma/biotech acquisition. BD
BOSTON (Thomson Financial) - Bayer AG's Bayer HealthCare Wednesday said has agreed to acquire Maxygen Inc.'s hemophilia program assets for $90 million with a final, potential milestone payment of $30 million. The agreement includes a next-generation recombinant Factor VIIa protein, known as MAXY-VII, and a license to use Maxygen's molecular breeding technology for exploiting gene targets. Bayer HealthCare said the agreement fits into its growth strategy for its specialty pharmaceutical business.
stocks, shares, news, FTSE, online trading - Interactive Investor
0 comments :
Post a Comment